| Return on investment from childhood immunization in low-and middle-income countries, 2011–20 S Ozawa, S Clark, A Portnoy, S Grewal, L Brenzel, DG Walker Health Affairs 35 (2), 199-207, 2016 | 404 | 2016 |
| Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study M Jit, M Brisson, A Portnoy, R Hutubessy The Lancet Global health 2 (7), e406-e414, 2014 | 310 | 2014 |
| Modeling the economic burden of adult vaccine-preventable diseases in the United States S Ozawa, A Portnoy, H Getaneh, S Clark, M Knoll, D Bishai, HK Yang, ... Health Affairs 35 (11), 2124-2132, 2016 | 196 | 2016 |
| Estimated economic impact of vaccinations in 73 low-and middle-income countries, 2001–2020 S Ozawa, S Clark, A Portnoy, S Grewal, ML Stack, A Sinha, A Mirelman, ... Bulletin of the World Health Organization 95 (9), 629, 2017 | 185 | 2017 |
| Progress toward measles elimination—worldwide, 2000–2022 AA Minta MMWR. Morbidity and Mortality Weekly Report 72, 2023 | 156 | 2023 |
| Progress toward regional measles elimination—worldwide, 2000–2020 MG Dixon, M Ferrari, S Antoni, X Li, A Portnoy, B Lambert, S Hauryski, ... MMWR. Morbidity and Mortality Weekly Report, 2021 | 137 | 2021 |
| Vaccine equity in low and middle income countries: a systematic review and meta-analysis HA Ali, AM Hartner, S Echeverria-Londono, J Roth, X Li, K Abbas, ... International journal for equity in health 21 (1), 82, 2022 | 134 | 2022 |
| Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis A Portnoy, M Jit, M Ferrari, M Hanson, L Brenzel, S Verguet The Lancet Global Health 7 (4), e472-e481, 2019 | 106 | 2019 |
| Costs of vaccine programs across 94 low-and middle-income countries A Portnoy, S Ozawa, S Grewal, BA Norman, J Rajgopal, KM Gorham, ... Vaccine 33, A99-A108, 2015 | 95 | 2015 |
| Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world J Toor, S Echeverria-Londono, X Li, K Abbas, ED Carter, HE Clapham, ... Elife 10, e67635, 2021 | 94 | 2021 |
| Progress toward regional measles elimination—worldwide, 2000–2021 AA Minta, M Ferrari, S Antoni, A Portnoy, A Sbarra, B Lambert, S Hauryski, ... MMWR. Morbidity and Mortality Weekly Report, 2022 | 85 | 2022 |
| Impact of measles supplementary immunization activities on reaching children missed by routine programs A Portnoy, M Jit, S Helleringer, S Verguet Vaccine 36 (1), 170-178, 2018 | 69 | 2018 |
| Producing standardized country-level immunization delivery unit cost estimates A Portnoy, K Vaughan, E Clarke-Deelder, C Suharlim, SC Resch, ... Pharmacoeconomics 38, 995-1005, 2020 | 48 | 2020 |
| Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis K Prem, YH Choi, É Bénard, EA Burger, L Hadley, JF Laprise, MC Regan, ... BMC medicine 21 (1), 313, 2023 | 43 | 2023 |
| Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low-and middle-income countries C Munk, A Portnoy, C Suharlim, E Clarke-Deelder, L Brenzel, SC Resch, ... BMC health services research 19, 1-10, 2019 | 42 | 2019 |
| Estimating costs of care for meningitis infections in low-and middle-income countries A Portnoy, M Jit, J Lauer, A Blommaert, S Ozawa, M Stack, J Murray, ... Vaccine 33, A240-A247, 2015 | 40 | 2015 |
| Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: a model-based analysis A Portnoy, K Pedersen, L Trogstad, BT Hansen, B Feiring, I Laake, ... Preventive medicine 144, 106276, 2021 | 32 | 2021 |
| Choosing the optimal HPV vaccine: the health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi‐eligible countries EA Burger, A Portnoy, NG Campos, S Sy, C Regan, JJ Kim International Journal of Cancer 148 (4), 932-940, 2021 | 31 | 2021 |
| The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study RA Clark, C Mukandavire, A Portnoy, CK Weerasuriya, A Deol, ... The Lancet Global Health 11 (4), e546-e555, 2023 | 27 | 2023 |
| The cost and cost-effectiveness of novel tuberculosis vaccines in low-and middle-income countries: A modeling study A Portnoy, RA Clark, M Quaife, CK Weerasuriya, C Mukandavire, ... PLoS medicine 20 (1), e1004155, 2023 | 26 | 2023 |
